Malaga Cove Capital LLC recently acquired a new stake in Kenvue Inc. (NYSE:KVUE), purchasing 11,975 shares valued at approximately $256,000 in the fourth quarter, according to their disclosure with the Securities & Exchange Commission. Other institutional investors and hedge funds have also adjusted their positions in Kenvue.

Handelsbanken Fonder AB increased its holdings by 2.9% in the fourth quarter, now owning 742,184 shares valued at $15,846,000 after acquiring an additional 21,222 shares. Alberta Investment Management Corp grew its stake by 23.2% during the same period, holding 582,895 shares worth $12,445,000 after purchasing 109,700 additional shares. Longbow Finance SA increased its stake by 5.0% in the fourth quarter, now owning 280,568 shares valued at $5,990,000 after buying an additional 13,287 shares.

Steward Partners Investment Advisory LLC increased its stake significantly by 143.1% in the fourth quarter, owning 47,938 shares valued at $1,023,000 after buying 28,216 additional shares. CORDA Investment Management LLC increased its stake by 1.4% in the same quarter, now holding 1,253,096 shares valued at $26,754,000 after acquiring 17,466 additional shares. Overall, institutional investors and hedge funds own 97.64% of Kenvue's stock.

Several research analysts have provided ratings and price objectives for KVUE shares. Evercore ISI initiated coverage with an "in-line" rating and a $25.00 price objective. Redburn Atlantic started coverage with a "neutral" rating and a $23.50 price objective. UBS Group raised its price objective from $24.00 to $25.00, maintaining a "neutral" rating. Citigroup also increased its price objective from $22.00 to $24.50, with a "neutral" rating. Royal Bank of Canada reaffirmed a "sector perform" rating and a $24.00 price objective. Currently, Kenvue has a consensus rating of "Hold" and an average target price of $25.33.

Kenvue's stock opened at $23.26 on Thursday, with a market capitalization of $44.63 billion, a price-to-earnings ratio of 43.89, a PEG ratio of 2.62, and a beta of 1.02. The stock's 52-week range is between $17.67 and $25.17. The 50-day moving average price is $23.15, and the 200-day moving average price is $22.58. The company's financial ratios include a debt-to-equity ratio of 0.66, a quick ratio of 0.69, and a current ratio of 1.00.

Kenvue reported its latest quarterly earnings on May 8th, with $0.24 earnings per share (EPS), exceeding analysts' estimates of $0.23. The company's return on equity is 20.97%, and the net margin is 6.66%. Revenue for the quarter was $3.74 billion, compared to analysts' expectations of $3.69 billion, but down 3.9% compared to the same quarter last year. Equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue recently announced a quarterly dividend of $0.205 per share, payable on May 28th to investors of record on May 14th. This equates to an annualized dividend of $0.82 and a yield of 3.53%. The ex-dividend date was May 14th. Kenvue's dividend payout ratio is currently 149.09%.

Kenvue Inc. operates as a consumer health company with three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers products under brands such as Tylenol, Motrin, Benadryl, Nicorette, and Zyrtec.